Comparative risk of serious infection in patients with ulcerative colitis treated with JAK inhibitors - PubMed
2 hours ago
- #JAK inhibitors
- #serious infection risk
- #ulcerative colitis
- Tofacitinib, upadacitinib, and filgotinib show similar risks of serious infection in ulcerative colitis patients.
- Infection risk is primarily dose-dependent, with higher doses of upadacitinib and tofacitinib linked to increased risk.
- Upadacitinib had the highest incidence rate of serious infections (38.8 per 1000 patient-years), while filgotinib had the lowest (28.4).
- No significant differences were found across infection sites or pathogen types among the JAK inhibitors.
- Upadacitinib was associated with the highest risk of non-severe infections, particularly from herpes simplex and varicella zoster viruses.